Signals, Powered By EquityPandit
Syngene International, Biocon’s contract research arm has extended its current drug discovery and development with US based Bristol-Myers Squibb till 2026.
In a BSE filing Syngene International stated, “The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026.”
Further it added, “The expansion will enable the two companies to undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities.”
Under the expansion plan, Syngene will be setting up new facility, which will be spread over 25,000 square feet of laboratory and office space for Bristol-Myers Squibb and an additional team of 75 Syngene scientists working entirely for Bristol.
